Cognitive Enhancement & Neuroprotection
Peptide-based cognitive enhancement ranges from FDA-approved treatments for neurological disease (ziconotide for pain, tesamorelin for cognitive effects in HIV) to preliminary nootropics with human trial data (Semax, Selank) to highly speculative compounds with only animal data (Dihexa, P21). Evidence quality varies enormously across this category.
Relevant Peptides
Russia-approved; BDNF upregulation; stroke recovery RCTs.
Russia-approved; anxiolytic without dependence; human trials.
Animal data impressive; no human trials; HGF/MET oncogenic risk.
Single rodent study; essentially no evidence base.
Mixed evidence; sleep and stress effects.
Russian research only; circadian/neuroprotection.
Primate cognitive data; no human trials.
Alzheimer's animal models; human correlational data.
The Russian Research Divide
A significant portion of the cognitive peptide evidence base comes from Russian clinical research — Semax and Selank specifically are approved and clinically used in Russia. This creates an evidence quality challenge: the research is real, peer-reviewed, and published, but largely conducted by a single research ecosystem with limited independent Western replication.
The evidence is: real but geographically concentrated.
The Dihexa Hype Problem
Dihexa’s animal cognition data is genuinely impressive, but no human data exists, and the HGF/MET oncogenic risk is a real, documented safety concern. The nootropic community’s enthusiasm significantly exceeds what the evidence supports. Apply maximal skepticism.
What Has The Best Evidence
For practitioners seeking evidence-based cognitive peptide options:
- Semax: Multiple human RCTs (stroke, cognitive impairment), approved drug in Russia
- Selank: Multiple human RCTs (anxiety, cognition), approved drug in Russia
- Tesamorelin: Phase II cognitive data in HIV/elderly via IGF-1
Stay current on peptide evidence
Weekly regulatory updates and study breakdowns. Free.